MASI
$175.97
Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide. It offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure...
Recent News
3 Overrated Stocks We Steer Clear Of
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.
This Fund Built a $26 Million Stake in a Medical Tech Stock That's Soaring After a $9.9 Billion Deal Announcement
This medical technology firm delivers advanced noninvasive monitoring and automation solutions to healthcare providers worldwide.
Patient Monitoring Stocks Q3 Recap: Benchmarking Masimo (NASDAQ:MASI)
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how patient monitoring stocks fared in Q3, starting with Masimo (NASDAQ:MASI).
1 Cash-Producing Stock on Our Buy List and 2 We Brush Off
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Assessing Masimo (MASI) Valuation After Recent Share Price Rebound And Mixed Fair Value Signals
Why Masimo is on investors’ radar Masimo (MASI) has been drawing attention after recent share price moves, with the stock showing double digit returns over the past month and past 3 months while its 1 year total return remains negative. See our latest analysis for Masimo. For Masimo, the recent strength in its share price, with a 30 day share price return of 27.69% and 90 day share price return of 26.99%, contrasts with a 1 year total shareholder return decline of 4.42%. This suggests...